These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 34650860)

  • 1. Memantine for the Treatment of Behavioral Disturbance in Unspecified Major Neurocognitive Disorder.
    Terry PH; Seoudy K; Lee MS; Stevenson KA
    Cureus; 2021 Sep; 13(9):e17685. PubMed ID: 34650860
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnostic utility of Montreal Cognitive Assessment in the Fifth Edition of Diagnostic and Statistical Manual of Mental Disorders: major and mild neurocognitive disorders.
    Liew TM; Feng L; Gao Q; Ng TP; Yap P
    J Am Med Dir Assoc; 2015 Feb; 16(2):144-8. PubMed ID: 25282632
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Retrospective study on the benefits of combined Memantine and cholinEsterase inhibitor treatMent in AGEd Patients affected with Alzheimer's Disease: the MEMAGE study.
    Gareri P; Putignano D; Castagna A; Cotroneo AM; De Palo G; Fabbo A; Forgione L; Giacummo A; Lacava R; Marino S; Simone M; Zurlo A; Putignano S
    J Alzheimers Dis; 2014; 41(2):633-40. PubMed ID: 24643135
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Memantine for dementia.
    Areosa SA; Sherriff F
    Cochrane Database Syst Rev; 2003; (3):CD003154. PubMed ID: 12917950
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effects of memantine on behavioral disturbances in patients with Alzheimer's disease: a meta-analysis.
    Kishi T; Matsunaga S; Iwata N
    Neuropsychiatr Dis Treat; 2017; 13():1909-1928. PubMed ID: 28790827
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Withdrawal or continuation of cholinesterase inhibitors or memantine or both, in people with dementia.
    Parsons C; Lim WY; Loy C; McGuinness B; Passmore P; Ward SA; Hughes C
    Cochrane Database Syst Rev; 2021 Feb; 2(2):CD009081. PubMed ID: 35608903
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Memantine for dementia.
    Areosa SA; Sherriff F
    Cochrane Database Syst Rev; 2003; (1):CD003154. PubMed ID: 12535459
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nursing home placement in the Donepezil and Memantine in Moderate to Severe Alzheimer's Disease (DOMINO-AD) trial: secondary and post-hoc analyses.
    Howard R; McShane R; Lindesay J; Ritchie C; Baldwin A; Barber R; Burns A; Dening T; Findlay D; Holmes C; Jones R; Jones R; McKeith I; Macharouthu A; O'Brien J; Sheehan B; Juszczak E; Katona C; Hills R; Knapp M; Ballard C; Brown RG; Banerjee S; Adams J; Johnson T; Bentham P; Phillips PP
    Lancet Neurol; 2015 Dec; 14(12):1171-81. PubMed ID: 26515660
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sustained effects of once-daily memantine treatment on cognition and functional communication skills in patients with moderate to severe Alzheimer's disease: results of a 16-week open-label trial.
    Schulz JB; Rainer M; Klünemann HH; Kurz A; Wolf S; Sternberg K; Tennigkeit F
    J Alzheimers Dis; 2011; 25(3):463-75. PubMed ID: 21471647
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Memantine ER, a once-daily formulation for the treatment of Alzheimer's disease.
    Bassil N; Thaipisuttikul P; Grossberg GT
    Expert Opin Pharmacother; 2010 Jul; 11(10):1765-71. PubMed ID: 20540654
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Memantine for dementia.
    McShane R; Westby MJ; Roberts E; Minakaran N; Schneider L; Farrimond LE; Maayan N; Ware J; Debarros J
    Cochrane Database Syst Rev; 2019 Mar; 3(3):CD003154. PubMed ID: 30891742
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antipsychotic dose-sparing effect with addition of memantine.
    Sleeper RB
    Ann Pharmacother; 2005 Sep; 39(9):1573-6. PubMed ID: 16076907
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Memantine for dementia.
    Areosa Sastre A; McShane R; Sherriff F
    Cochrane Database Syst Rev; 2004 Oct; (4):CD003154. PubMed ID: 15495043
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Montreal Cognitive Assessment as Screening Measure for Mild and Major Neurocognitive Disorder in a Chilean Population.
    Bello-Lepe S; Alonso-Sánchez MF; Ortega A; Gaete M; Veliz M; Lira J; Perez Salas CP
    Dement Geriatr Cogn Dis Extra; 2020; 10(3):105-114. PubMed ID: 33250917
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The neurocognitive disorder cohort RIFADE: Aims, methods, first results showing cognitive improvement in a subgroup.
    Baumann B; Lipka T; Jänner M; Kujovic M
    Eur Arch Psychiatry Clin Neurosci; 2023 Jun; 273(4):941-952. PubMed ID: 36416960
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Memantine ameliorates learning and memory disturbance and the behavioral and psychological symptoms of dementia in thiamine-deficient mice.
    Makino M; Takahashi-Ito K; Murasawa H; Pawlak A; Kashimoto Y; Kitano Y
    Pharmacol Biochem Behav; 2019 Aug; 183():6-13. PubMed ID: 31175916
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment strategies for the behavioral symptoms of Alzheimer's disease: focus on early pharmacologic intervention.
    Beier MT
    Pharmacotherapy; 2007 Mar; 27(3):399-411. PubMed ID: 17316151
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination therapy with cholinesterase inhibitors and memantine for Alzheimer's disease: a systematic review and meta-analysis.
    Matsunaga S; Kishi T; Iwata N
    Int J Neuropsychopharmacol; 2014 Dec; 18(5):. PubMed ID: 25548104
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Memantine effects measured with the Relevant Outcome Scale for Alzheimer's disease in an open-label, single-arm, multicenter clinical study.
    Holthoff V; Ferris S; Gauthier S; Ihl R; Robert P; Winblad B; Sternberg K; Tennigkeit F;
    Int J Geriatr Psychiatry; 2013 Feb; 28(2):164-72. PubMed ID: 22492589
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.